Stratasan’s Market Reimbursement Analyzer (MRA) code set has been updated, making a greater volume of claims accessible to our partners. This increased volume means our customers will have a more robust data foundation to build upon for making informed decisions around negotiation strategy and financially based strategic planning.
This updated code set is available to customers beginning March 22, 2022.
With this update, we’ll be including codes that are not typically reimbursed by Medicare. This includes E&M codes specific to pediatrics, neonatal inpatient, GI, and obstetrics.
The goal of this enhancement is to give our partners a broader and more comprehensive view of the market and access to a greater volume of claims via MRA.
The additional data included has been extensively tested by the Stratasan Data Science team to ensure its reliability. If you have any questions about this update, please reach out to your Customer Success Manager or email customersuccess@stratasan.com.
